Sp113
NON-INVASIVE DETECTION OF PANCREATIC CYSTS AND CANCERS
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
For years, presentations at DDW focused on endoscopic diagnosis of pancreatic cystic neoplasms. There has been a recent surge of published studies testing various interventions for treating cystic neoplasms (endoscopic ultrasound-guided). This session will put these studies in perspective and compare them with surgical resection on the one hand and surveillance on the other.
For years, presentations at DDW focused on endoscopic diagnosis of pancreatic cystic neoplasms. There has been a recent surge of published studies testing various interventions for treating cystic neoplasms (endoscopic ultrasound-guided). This session will put these studies in perspective and compare them with surgical resection on the one hand and surveillance on the other.
Presenter
Tracks
Related Products
PANEL DISCUSSION
For years, presentations at DDW focused on endoscopic diagnosis of pancreatic cystic neoplasms. There has been a recent surge of published studies testing various interventions for treating cystic neoplasms (endoscopic ultrasound-guided)…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
